What is the 13F Pro Quality Score for AKBA?

13F Pro ranks Akebia Therapeutics, Inc. (AKBA) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AKBA's current score at https://13fpro.ai/company/AKBA (free sign-up required for the full ranking).

Which hedge funds own the most AKBA stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of AKBA include BlackRock,, VANGUARD CAPITAL MANAGEMENT, AQR CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/AKBA as soon as new 13F filings post.

Where does 13F Pro source AKBA data?

All Akebia Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Akebia Therapeutics, Inc. files with the SEC under CIK 1517022. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AKBA in?

Akebia Therapeutics, Inc. (AKBA) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AKBA research updated on 13F Pro?

AKBA's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Akebia Therapeutics, Inc.(AKBA)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1517022 AKBA stock profile & AI dashboard →

13F Pro Quality Score

45.3/100

Rank #1,874 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

65.2/100

Profitability

22.2/100

Balance Sheet

18.6/100

Earnings Quality

71.9/100

Free Cash Flow

70.8/100

Institutional Flow

38.4/100

Revenue Scale

25.0/100

Dilution Risk

25.5/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why AKBA Scores 45/100

exact factor attribution · 2026-09-11

AKBA's composite is driven by free cash flow and revenue growth, held back by profitability and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Free cash flow

+3.1 pts

71th pct

Revenue growth

+3.0 pts

65th pct

Earnings quality

+2.2 pts

72th pct

Earnings growth

-0.2 pts

47th pct

Institutional flow

-0.6 pts

38th pct

Shareholder dilution

-1.2 pts

26th pct

Capital efficiency

-3.1 pts

19th pct

Scale

-3.8 pts

25th pct

Profitability

-4.2 pts

22th pct

Latest change (2026-08-05): 46 → 40 · ↓ Revenue growth 77→55; ↓ Profit margin 51→33; despite ↑ Free cash flow 55→78

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

AKBA Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Akebia Therapeutics, Inc. (AKBA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AKBA at 45.3/100 on a 32-signal composite quality model, placing it at rank #1,874 of 2,962 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (18.6) and profitability (22.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Akebia Therapeutics, Inc. reports quarterly revenue of $49.1M, net income of $-8.9M, free cash flow of $2.4M. Top institutional holders of AKBA by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, AQR CAPITAL MANAGEMENT, based on the most recent SEC filings. AKBA trades on the Nasdaq exchange and files with the SEC under CIK 1517022. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AKBA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Akebia Therapeutics, Inc. directly from SEC EDGAR. Akebia Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 11 and 54 since 2021, currently 45.3 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Akebia Therapeutics, Inc.

Quirks, history, and lore behind AKBA — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biopharmaceutical company · small-cap · listed on Nasdaq · headquartered in Massachusetts.
2
The Numbers
Annual revenue in the tens of millions of dollars — the profile of a company still fighting to prove its lead drug can carry the whole business.
3
The History
Founded in the 2000s, it spent years developing therapies targeting chronic kidney disease, a condition affecting hundreds of millions of people worldwide.
4
The Secret
Its core science centers on the HIF pathway — hypoxia-inducible factor — a molecular switch the body uses to respond to low oxygen levels, which also governs red blood cell production.
5
The Lore
Its lead drug, a HIF prolyl hydroxylase inhibitor, went head-to-head with dialysis-era anemia treatments in a notably rocky regulatory journey with the FDA — a saga that tested investors' patience for years.
6
The Giveaway
The company's name is a mashup of two Greek roots meaning 'no' and 'life' — fitting for a firm obsessed with what happens when kidneys fail and blood stops carrying enough oxygen.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$49.1M

Net Income

Q2 2026

$-8.9M

Free Cash Flow

Q2 2026

$2.4M

ROIC

Q2 2026

-25.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+47.5% YoY

$236.2MFY 2025

FY22 $292.5MFY23 $194.6MFY24 $160.2MFY25 $236.2M

Net Income

+92.3% YoY

$-5.3MFY 2025

FY22 $-94.2MFY23 $-51.9MFY24 $-69.4MFY25 $-5.3M

Operating Income

+146.6% YoY

$23.5MFY 2025

FY22 $-80.8MFY23 $-46.3MFY24 $-50.5MFY25 $23.5M

EPS (Diluted)

+93.9% YoY

$-0.02FY 2025

FY22 $-0.52FY23 $-0.28FY24 $-0.33FY25 $-0.02

Total Assets

+70.6% YoY

$376.6MFY 2025

FY22 $356.1MFY23 $241.7MFY24 $220.7MFY25 $376.6M

Total Debt

+24.7% YoY

$48.3MFY 2025

FY22 $98.1MFY23 $52.2MFY24 $38.7MFY25 $48.3M

Op. Cash Flow

+267.2% YoY

$68.0MFY 2025

FY22 $-73.2MFY23 $-23.4MFY24 $-40.7MFY25 $68.0M

Free Cash Flow

+266.4% YoY

$67.7MFY 2025

FY22 $-73.3MFY23 $-23.4MFY24 $-40.7MFY25 $67.7M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$236.2M +47.5%	$160.2M -17.7%	$194.6M -33.5%	$292.5M +38.2%	$211.7M -28.2%	$294.6M
Net Income	$-5.3M +92.3%	$-69.4M -33.7%	$-51.9M +44.9%	$-94.2M +66.6%	$-282.0M +26.7%	$-384.8M
Operating Income	$23.5M +146.6%	$-50.5M -9.1%	$-46.3M +42.7%	$-80.8M +69.5%	$-264.5M +30.0%	$-377.8M
EPS (Diluted)	$-0.02 +93.9%	$-0.33 -17.9%	$-0.28 +46.2%	$-0.52 +69.4%	$-1.70 +38.8%	$-2.78
Total Assets	$376.6M +70.6%	$220.7M -8.7%	$241.7M -32.1%	$356.1M -32.7%	$529.3M -17.8%	$644.1M
Total Debt	$48.3M +24.7%	$38.7M -25.9%	$52.2M -46.8%	$98.1M -49.7%	$195.1M +102.4%	$96.4M
Operating Cash Flow	$68.0M +267.2%	$-40.7M -73.9%	$-23.4M +68.0%	$-73.2M +71.1%	$-253.0M -129.2%	$-110.4M
Free Cash Flow	$67.7M +266.4%	$-40.7M -74.0%	$-23.4M +68.1%	$-73.3M +71.0%	$-253.0M -128.6%	$-110.7M

Get alerted when AKBA's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Akebia Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AKBA

BlackRock, Inc.
$22.8M19,986,374 sh
VANGUARD CAPITAL MANAGEMENT LLC
$12.9M11,322,143 sh
AQR CAPITAL MANAGEMENT LLC
$10.4M9,151,524 sh
GEODE CAPITAL MANAGEMENT, LLC
$7.7M6,727,302 sh
STATE STREET CORP
$6.1M5,390,853 sh
JACOBS LEVY EQUITY MANAGEMENT, INC
$4.9M4,273,026 sh
ACADIAN ASSET MANAGEMENT LLC
$4.6M4,004,867 sh
GOLDMAN SACHS GROUP INC
$4.2M3,689,167 sh
MILLENNIUM MANAGEMENT LLC
$3.6M3,196,605 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$2.9M2,533,977 sh

Fund	Value	Shares
BlackRock, Inc.	$22.8M	19,986,374
VANGUARD CAPITAL MANAGEMENT LLC	$12.9M	11,322,143
AQR CAPITAL MANAGEMENT LLC	$10.4M	9,151,524
GEODE CAPITAL MANAGEMENT, LLC	$7.7M	6,727,302
STATE STREET CORP	$6.1M	5,390,853
JACOBS LEVY EQUITY MANAGEMENT, INC	$4.9M	4,273,026
ACADIAN ASSET MANAGEMENT LLC	$4.6M	4,004,867
GOLDMAN SACHS GROUP INC	$4.2M	3,689,167
MILLENNIUM MANAGEMENT LLC	$3.6M	3,196,605
VANGUARD PORTFOLIO MANAGEMENT LLC	$2.9M	2,533,977

Companies Similar to AKBA

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

TVTX

Travere Therapeutics, Inc.

AI score

Similar quality profile · 5 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Hennion & Walsh Asset Management, Inc.Eversept Partners, LP

LFCR

LIFECORE BIOMEDICAL, INC. DE

AI score

Similar quality profile · 1 shared holders

R Squared Ltd

BCRX

BIOCRYST PHARMACEUTICALS INC

AI score

Similar quality profile · 7 shared holders

Nantahala Capital Management, LLC Hennion & Walsh Asset Management, Inc.Eversept Partners, LP

TARS

Tarsus Pharmaceuticals, Inc.

AI score

Similar quality profile · 2 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Eversept Partners, LP

HROW

HARROW, INC.

AI score

Similar quality profile · 4 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC Scientech Research LLC Sonora Investment Management Group, LLC

XERS

Xeris Biopharma Holdings, Inc.

AI score

Similar quality profile

SMTI

Sanara MedTech Inc.

AI score

Similar quality profile · 1 shared holders

JACOBS LEVY EQUITY MANAGEMENT, INC

ECVT

Ecovyst Inc.

AI score

Similar quality profile · 3 shared holders

MANGROVE PARTNERS IM, LLC CWA Asset Management Group, LLC Clear Harbor Asset Management, LLC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AKBA on your watchlist

Track score changes the day Akebia Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AKBA a good stock to buy?

13F Pro's AI-powered analysis of Akebia Therapeutics, Inc. (AKBA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AKBA are available on the AKBA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. AKBA is classified as a small company.

Which hedge funds own AKBA?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AKBA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Akebia Therapeutics, Inc.'s investment landscape.